Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.

[1]  O. Horstick,et al.  Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy. , 2019, American journal of public health.

[2]  M. Yamabhai,et al.  CD4+ T cells promote humoral immunity and viral control during Zika virus infection , 2019, PLoS pathogens.

[3]  R. DiPaolo,et al.  CD4+T cells mediate protection against Zika associated severe disease in a mouse model of infection , 2018, PLoS pathogens.

[4]  H. Schuitemaker,et al.  Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge , 2018, PloS one.

[5]  A. Iwasaki,et al.  Critical role of CD4+ T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection , 2018, Nature Communications.

[6]  Galit Alter,et al.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) , 2018, The Lancet.

[7]  D. Barouch,et al.  Zika virus vaccines , 2018, Nature Reviews Microbiology.

[8]  P. Saá,et al.  Investigational Testing for Zika Virus among U.S. Blood Donors , 2018, The New England journal of medicine.

[9]  Alison E Kosel,et al.  Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials , 2017, The Lancet.

[10]  Gregory D. Gromowski,et al.  Durability and correlates of vaccine protection against Zika virus in rhesus monkeys , 2017, Science Translational Medicine.

[11]  Stephen J. Thomas,et al.  Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States , 2017, The American journal of tropical medicine and hygiene.

[12]  C. Dye,et al.  Zika Virus Infection and Associated Neurologic Disorders in Brazil. , 2017, The New England journal of medicine.

[13]  Catherine M. Brown,et al.  Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy , 2017, JAMA.

[14]  Jessica Jimenez,et al.  Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys , 2016, Science.

[15]  Richard G. Jarman,et al.  Vaccine Protection Against Zika Virus from Brazil , 2016, Nature.

[16]  A. Act,et al.  Zika Virus Infection in Pregnant Women in Rio de Janeiro - Preliminary Report. , 2016 .

[17]  Anthony S Fauci,et al.  Zika Virus in the Americas--Yet Another Arbovirus Threat. , 2016, The New England journal of medicine.

[18]  Stephen J. Thomas,et al.  Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial , 2015, The American journal of tropical medicine and hygiene.

[19]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[20]  Carolyn D. Rysgaard,et al.  Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem , 2012, BMC Clinical Pathology.

[21]  C. Klade,et al.  Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. , 2011, Vaccine.

[22]  Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. , 2011, MMWR. Morbidity and mortality weekly report.

[23]  C. Klade,et al.  Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. , 2010, Vaccine.

[24]  J. Kaldor,et al.  Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[25]  C. Klade,et al.  Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. , 2008, Vaccine.

[26]  Karl A. Western,et al.  National Institute of Allergy and Infectious Diseases (NIAID): An Overview , 2008 .

[27]  B. Grossman,et al.  Hepatitis B surface antigenemia in blood donors following vaccination , 1995, Transfusion.